Induztr
Résumé technique Visionneuse de documents Modèles associés

CQA Assessment of LNP-mRNA Drug Products

Sommaire

  1. Overview p. 1
    Introduction to CQA assessment of LNP-mRNA
  2. Procedure p. 2
    Analytical methods used for assessment
  3. Spec p. 3
    Average sizing results for Fluc mRNA
  4. Spec p. 4
    Accuracy and precision of sizing measurements
  5. Spec p. 5
    Analysis of 9,400 nt IVT mRNA drug product
  6. Spec p. 6
    Precision of Fluc IVT mRNA quantification
  7. p. 7
    Summary of CQA assessment findings

Engineering Facts

11 facts · every claim linked to a page
Operation

LNP-encapsulated IVT mRNA must be disrupted with surfactant before capillary electrophoresis analysis to release the mRNA.

Defines the required sample prep step before running the assay on the instrument.

Source
“Prior to analysis, the drug products were disrupted with varying amounts of surfactant for 20 minutes at room temperature.”
Selection

The HS RNA kit specifications are based on non-encapsulated IVT mRNA, so LNP formulations may need method optimization.

Prevents assuming kit specs transfer directly to proprietary LNP drug products.

Source
“HS RNA Kit specifications for IVT mRNA analysis are based upon commercially available IVT mRNA, not LNP-encapsulated IVT mRNA.”
Operation

Surfactant concentration directly controls how much mRNA is released, so it must be optimized per LNP formulation.

Guides disruption optimization to avoid under- or over-release of mRNA.

Source
“increasing the concentration of surfactant used to disrupt the LNP resulted in an increase in the amount of mRNA released.”
Performance

Sizing accuracy and precision stay well within assay specs across the quantitative range for both drug substance and drug product.

Confirms the method meets the 15% error and 5% CV specifications for integrity CQA.

Source
“Each sample displayed an average sizing accuracy below 4% error, and precision of 1% CV or less”
Performance

The standard method is validated for sizing accuracy and precision down to 1 ng/µL, below the stated quantitative range.

Allows reliable sizing of low-concentration samples without rework.

Source
“Samples were also assessed below the quantitative range of the method, at 1 ng/µL, and still showed excellent accuracy and precision of sizing.”
Selection

Extended Method BE is needed for IVT mRNAs longer than 6,000 nt.

Determines which method to select for long IVT mRNA constructs.

Source
“Extended methods have been optimized for analysis of sample sizes larger than 6,000 nt.”
Operation

For large mRNAs, a 1:1 or 1:2 sample-to-surfactant ratio gives accurate sizing.

Specifies the disruption ratio to use for 9,400 and 11,000 nt samples.

Source
“Surfactant was added to the samples at a 1:1 or a 1:2 ratio to determine the optimal disruption conditions of these larger sized samples.”
Performance

Quantification precision is under 6% CV across runs and 3.3% CV within a run after LNP disruption.

Supports using the system for reliable drug product quantification.

Source
“with less than 6 %CV across all three runs.”
Performance

Purity (percent total) measurements are precise to within 3% CV for both drug substance and drug product.

Confirms the smear analysis is stable enough for purity CQA reporting.

Source
“with no more than 3 %CV for either sample.”
Selection

Standard and high-sensitivity RNA kits cover broad concentration ranges to match different sample needs.

Informs kit selection based on expected sample concentration.

Source
“Standard and high-sensitivity RNA kits are available to cover broad concentration ranges for IVT mRNA”
Conformité

The system is for research use only and not for diagnostic procedures.

Restricts deployment to non-diagnostic applications.

Source
“For Research Use Only. Not for use in diagnostic procedures.”